Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient performance status, and comorbidities while weighing the pros and cons of current options—such as chemotherapy-sparing regimens, androgen receptor pathway inhibitor (ARPI) selection, and the use of triplet versus doublet combination therapies—to optimize efficacy and minimize adverse effects based on each patient’s unique clinical profile.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

Now Viewing

EP: 4.Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

Video content above is prompted by the following:

1. Please discuss how you approach individualized first-line systemic therapy selection for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
   1. Please offer perspectives on pros/cons of current options for first-line therapy.
   2. What factors do you consider during treatment decision-making (eg, use of chemotherapy-sparing regimens, ARPI selection, triplet versus doublet combination systemic therapy)?
      

Recent Videos